OraSure Technologies (NASDAQ:OSUR) Given "Sell (D)" Rating at Weiss Ratings

Key Points

• OraSure Technologies' stock has received a "Sell (D)" rating from Weiss Ratings, indicating concerns about the company's current financial health.
• The company's stock price ranges between a 1-year low of $2.36 and a high of $4.60, with a current market cap of $216.49 million.
• Approximately 93.50% of OraSure's shares are held by institutional investors and hedge funds, highlighting significant interest from large financial entities.

OraSure Technologies (NASDAQ:OSUR - Get Free Report)'s stock had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.

OraSure Technologies Price Performance

Shares of NASDAQ:OSUR opened at $2.96 on Friday. OraSure Technologies has a 1-year low of $2.36 and a 1-year high of $4.60. The stock has a market cap of $216.49 million, a P/E ratio of -4.42 and a beta of 0.46. The firm has a fifty day moving average price of $3.15 and a 200 day moving average price of $3.01.

Institutional Trading of OraSure Technologies

Hedge funds have recently added to or reduced their stakes in the stock. Spire Wealth Management acquired a new position in shares of OraSure Technologies in the first quarter valued at approximately $54,000. Jacobs Levy Equity Management Inc. grew its position in OraSure Technologies by 39.3% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,290,554 shares of the medical instruments supplier's stock valued at $4,349,000 after buying an additional 363,946 shares during the last quarter. Strs Ohio acquired a new position in OraSure Technologies in the 1st quarter valued at $481,000. Gagnon Securities LLC raised its position in OraSure Technologies by 49.4% during the 2nd quarter. Gagnon Securities LLC now owns 1,604,142 shares of the medical instruments supplier's stock worth $4,812,000 after buying an additional 530,371 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its stake in shares of OraSure Technologies by 32.9% in the 1st quarter. Bridgeway Capital Management LLC now owns 1,635,275 shares of the medical instruments supplier's stock worth $5,511,000 after acquiring an additional 405,169 shares during the period. 93.50% of the stock is owned by institutional investors and hedge funds.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.